BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate

BioAtla (NASDAQ: BCAB) reported Q4 earnings with an EPS of $(0.16), surpassing the analyst estimate of $(0.30) by 47.19%. This represents a 46.67% improvement from the $(0.30) loss per share in the same quarter last year. Additionally, the company achieved quarterly sales of $2.000 million, exceeding the consensus estimate of $700.000 thousand by 185.71%.